Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 557

1.

Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial.

Schöffski P, Sufliarsky J, Gelderblom H, Blay JY, Strauss SJ, Stacchiotti S, Rutkowski P, Lindner LH, Leahy MG, Italiano A, Isambert N, Debiec-Rychter M, Sciot R, Van Cann T, Marréaud S, Nzokirantevye A, Collette S, Wozniak A.

Lancet Respir Med. 2018 Apr 12. pii: S2213-2600(18)30116-4. doi: 10.1016/S2213-2600(18)30116-4. [Epub ahead of print]

PMID:
29669701
2.

Outcomes of Elderly Patients with Advanced Soft Tissue Sarcoma Treated with First-Line Chemotherapy: A Pooled Analysis of 12 EORTC Soft Tissue and Bone Sarcoma Group Trials.

Younger E, Litière S, Le Cesne A, Mir O, Gelderblom H, Italiano A, Marreaud S, Jones RL, Gronchi A, van der Graaf WTA.

Oncologist. 2018 Apr 12. pii: theoncologist.2017-0598. doi: 10.1634/theoncologist.2017-0598. [Epub ahead of print]

PMID:
29650688
3.

Denosumab treatment of inoperable or locally advanced giant cell tumor of bone - Multicenter analysis outside clinical trial.

Rutkowski P, Gaston L, Borkowska A, Stacchiotti S, Gelderblom H, Baldi GG, Palmerini E, Casali P, Gronchi A, Parry M, Campanacci DA, Scoccianti G, Wagrodzki M, Ferrari S, Dijkstra S, Pieńkowski A, Grimer R.

Eur J Surg Oncol. 2018 Mar 31. pii: S0748-7983(18)30989-2. doi: 10.1016/j.ejso.2018.03.020. [Epub ahead of print]

PMID:
29650420
4.

Mechanistic insights of an immunological adverse event induced by an anti-KIT antibody drug conjugate and mitigation strategies.

L'Italien LE, Orozco O, Abrams TJ, Cantagallo L, Connor A, Desai J, Ebersbach H, Gelderblom H, Hoffmaster K, Lees E, Maacke H, Schleyer S, Skegro D, Lee-Hoeflich ST.

Clin Cancer Res. 2018 Apr 3. pii: clincanres.3786.2017. doi: 10.1158/1078-0432.CCR-17-3786. [Epub ahead of print]

PMID:
29615457
5.

Prognostic relevance of distant metastases versus locally advanced disease in soft tissue sarcomas: An EORTC-STBSG database study.

Verschoor AJ, Litière S, Marréaud S, Judson I, Toulmonde M, Wardelmann E, van der Graaf WT, Le Cesne A, Gronchi A, Gelderblom H.

Eur J Cancer. 2018 May;94:187-198. doi: 10.1016/j.ejca.2018.02.015. Epub 2018 Mar 22.

PMID:
29574364
6.

Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial.

Gelderblom H, Cropet C, Chevreau C, Boyle R, Tattersall M, Stacchiotti S, Italiano A, Piperno-Neumann S, Le Cesne A, Ferraresi V, Penel N, Duffaud F, Cassier P, Toulmonde M, Casali P, Taieb S, Guillemaut S, Metzger S, Pérol D, Blay JY.

Lancet Oncol. 2018 Mar 20. pii: S1470-2045(18)30143-8. doi: 10.1016/S1470-2045(18)30143-8. [Epub ahead of print]

PMID:
29571946
7.

A single digital droplet PCR assay to detect multiple KIT exon 11 mutations in tumor and plasma from patients with gastrointestinal stromal tumors.

Boonstra PA, Ter Elst A, Tibbesma M, Bosman LJ, Mathijssen R, Atrafi F, van Coevorden F, Steeghs N, Farag S, Gelderblom H, van der Graaf WTA, Desar IME, Maier J, Overbosch J, Suurmeijer AJH, Gietema J, Schuuring E, Reyners AKL.

Oncotarget. 2018 Feb 14;9(17):13870-13883. doi: 10.18632/oncotarget.24493. eCollection 2018 Mar 2.

8.

Rapid Viral Diagnosis of Orthopoxviruses by Electron Microscopy: Optional or a Must?

Gelderblom HR, Madeley D.

Viruses. 2018 Mar 22;10(4). pii: E142. doi: 10.3390/v10040142. Review.

9.

Predictors for doxorubicin-induced hematological toxicity and its association with outcome in advanced soft tissue sarcoma patients; a retrospective analysis of the EORTC-soft tissue and bone sarcoma group database.

Sleijfer S, Rizzo E, Litière S, Mathijssen RHJ, Judson IR, Gelderblom H, Van Der Graaf WTA, Gronchi A.

Acta Oncol. 2018 Mar 9:1-10. doi: 10.1080/0284186X.2018.1449248. [Epub ahead of print]

PMID:
29521151
10.

Telatinib Is an Effective Targeted Therapy for Pseudomyogenic Hemangioendothelioma.

van IJzendoorn DGP, Sleijfer S, Gelderblom H, Eskens FALM, van Leenders GJLH, Szuhai K, Bovée JVMG.

Clin Cancer Res. 2018 Mar 6. doi: 10.1158/1078-0432.CCR-17-3512. [Epub ahead of print]

PMID:
29511030
11.

A Genetic Polymorphism in CTLA-4 Is Associated with Overall Survival in Sunitinib-Treated Patients with Clear Cell Metastatic Renal Cell Carcinoma.

Liu X, Swen JJ, Diekstra MHM, Boven E, Castellano D, Gelderblom H, Mathijssen RHJ, Vermeulen SH, Oosterwijk E, Junker K, Roessler M, Alexiusdottir K, Sverrisdottir A, Radu MT, Ambert V, Eisen T, Warren A, Rodríguez-Antona C, García-Donas J, Böhringer S, Koudijs KKM, Kiemeney LALM, Rini BI, Guchelaar HJ.

Clin Cancer Res. 2018 Feb 28. doi: 10.1158/1078-0432.CCR-17-2815. [Epub ahead of print]

PMID:
29490989
12.

Recurrence of Ewing sarcoma: Is detection by imaging follow-up protocol associated with survival advantage?

Heinemann M, Ranft A, Langer T, Jürgens H, Kreyer J, Vieth V, Schäfers M, Weckesser M, Simon T, Hassenpflug W, Corbacioglu S, Bielack S, Mayer-Steinacker R, Kühne T, van den Berg H, Gelderblom H, Bauer S, Stegger L, Dirksen U.

Pediatr Blood Cancer. 2018 Feb 26. doi: 10.1002/pbc.27011. [Epub ahead of print]

PMID:
29480574
13.

The tumour-stroma ratio in colon cancer: the biological role and its prognostic impact.

van Pelt GW, Sandberg TP, Morreau H, Gelderblom H, van Krieken JHJM, Tollenaar RAEM, Mesker WE.

Histopathology. 2018 Feb 19. doi: 10.1111/his.13489. [Epub ahead of print] Review.

PMID:
29457843
14.

Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).

Lindner LH, Litière S, Sleijfer S, Benson C, Italiano A, Kasper B, Messiou C, Gelderblom H, Wardelmann E, Le Cesne A, Blay JY, Marreaud S, Hindi N, Desar IME, Gronchi A, van der Graaf WTA.

Int J Cancer. 2018 Jun 15;142(12):2610-2620. doi: 10.1002/ijc.31286. Epub 2018 Feb 14.

PMID:
29383713
15.

A remarkable response to pazopanib, despite recurrent liver toxicity, in a patient with a high grade endometrial stromal sarcoma, a case report.

Verschoor AJ, Warmerdam FARM, Bosse T, Bovée JVMG, Gelderblom H.

BMC Cancer. 2018 Jan 22;18(1):92. doi: 10.1186/s12885-018-3999-0.

16.

The incidence, mutational status, risk classification and referral pattern of gastro-intestinal stromal tumours in the Netherlands: a nationwide pathology registry (PALGA) study.

Verschoor AJ, Bovée JVMG, Overbeek LIH; PALGA group, Hogendoorn PCW, Gelderblom H.

Virchows Arch. 2018 Feb;472(2):221-229. doi: 10.1007/s00428-017-2285-x. Epub 2018 Jan 8.

17.

Quality of life of patients with locally advanced head and neck cancer treated with induction chemotherapy followed by cisplatin-containing chemoradiotherapy in the Dutch CONDOR study: a randomized controlled trial.

Driessen CML, Groenewoud JMM, de Boer JP, Gelderblom H, van der Graaf WTA, Prins JB, Kaanders JHAM, van Herpen CML.

Support Care Cancer. 2018 Apr;26(4):1233-1242. doi: 10.1007/s00520-017-3946-7. Epub 2017 Dec 11.

18.

Are pathological high-risk features in locally advanced rectal cancer a useful selection tool for adjuvant chemotherapy?

Swets M, Kuppen PJK, Blok EJ, Gelderblom H, van de Velde CJH, Nagtegaal ID.

Eur J Cancer. 2018 Jan;89:1-8. doi: 10.1016/j.ejca.2017.11.006. Epub 2017 Dec 7.

PMID:
29223019
19.

Perioperative Management of Extremity Soft Tissue Sarcomas.

Haas RL, Gronchi A, van de Sande MAJ, Baldini EH, Gelderblom H, Messiou C, Wardelmann E, Le Cesne A.

J Clin Oncol. 2018 Jan 10;36(2):118-124. doi: 10.1200/JCO.2017.74.7527. Epub 2017 Dec 8.

PMID:
29220299
20.

Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'.

Schöffski P, Wozniak A, Kasper B, Aamdal S, Leahy MG, Rutkowski P, Bauer S, Gelderblom H, Italiano A, Lindner LH, Hennig I, Strauss S, Zakotnik B, Anthoney A, Albiges L, Blay JY, Reichardt P, Sufliarsky J, van der Graaf WTA, Debiec-Rychter M, Sciot R, Van Cann T, Marréaud S, Raveloarivahy T, Collette S, Stacchiotti S.

Ann Oncol. 2018 Mar 1;29(3):758-765. doi: 10.1093/annonc/mdx774.

PMID:
29216400
21.

Pharmacokinetics and safety of panitumumab in a patient with chronic kidney disease.

Krens LL, Baas JM, Guchelaar HJ, Gelderblom H.

Cancer Chemother Pharmacol. 2018 Jan;81(1):179-182. doi: 10.1007/s00280-017-3479-2. Epub 2017 Nov 23.

22.

Elderly patients with gastrointestinal stromal tumour (GIST) receive less treatment irrespective of performance score or comorbidity - A retrospective multicentre study in a large cohort of GIST patients.

Farag S, van Coevorden F, Sneekes E, Grunhagen DJ, Reyners AKL, Boonstra PA, van der Graaf WT, Gelderblom HJ, Steeghs N.

Eur J Cancer. 2017 Nov;86:318-325. doi: 10.1016/j.ejca.2017.09.017. Epub 2017 Oct 23.

PMID:
29073582
23.

Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib.

Verboom MC, Kloth JSL, Swen JJ, van der Straaten T, Bovée JVMG, Sleijfer S, Reyners AKL, Mathijssen RHJ, Guchelaar HJ, Steeghs N, Gelderblom H.

Eur J Cancer. 2017 Nov;86:226-232. doi: 10.1016/j.ejca.2017.09.025. Epub 2017 Oct 18.

PMID:
29054076
24.

Early Evaluation of Response Using 18F-FDG PET Influences Management in Gastrointestinal Stromal Tumor Patients Treated with Neoadjuvant Imatinib.

Farag S, Geus-Oei LF, van der Graaf WT, van Coevorden F, Grunhagen D, Reyners AKL, Boonstra PA, Desar I, Gelderblom H, Steeghs N.

J Nucl Med. 2018 Feb;59(2):194-196. doi: 10.2967/jnumed.117.196642. Epub 2017 Sep 28.

PMID:
28970330
25.

Apparatus to control and visualize the impact of a high-energy laser pulse on a liquid target.

Klein AL, Lohse D, Versluis M, Gelderblom H.

Rev Sci Instrum. 2017 Sep;88(9):095102. doi: 10.1063/1.4989634.

PMID:
28964175
26.

Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism.

Sanchez Spitman AB, Moes DJAR, Gelderblom H, Dezentje VO, Swen JJ, Guchelaar HJ.

Eur J Clin Pharmacol. 2017 Dec;73(12):1589-1598. doi: 10.1007/s00228-017-2323-2. Epub 2017 Aug 28.

27.

Higher incidence rates than previously known in tenosynovial giant cell tumors.

Mastboom MJL, Verspoor FGM, Verschoor AJ, Uittenbogaard D, Nemeth B, Mastboom WJB, Bovée JVMG, Dijkstra PDS, Schreuder HWB, Gelderblom H, Van de Sande MAJ; TGCT study group.

Acta Orthop. 2017 Dec;88(6):688-694. doi: 10.1080/17453674.2017.1361126. Epub 2017 Aug 8.

28.

Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma.

Stacchiotti S, Mir O, Le Cesne A, Vincenzi B, Fedenko A, Maki RG, Somaiah N, Patel S, Brahmi M, Blay JY, Boye K, Sundby Hall K, Gelderblom H, Hindi N, Martin-Broto J, Kosela H, Rutkowski P, Italiano A, Duffaud F, Kobayashi E, Casali PG, Provenzano S, Kawai A.

Oncologist. 2018 Jan;23(1):62-70. doi: 10.1634/theoncologist.2017-0161. Epub 2017 Jul 28.

PMID:
28754721
29.

The effect of rs5758550 on CYP2D6*2 phenotype and formation of endoxifen in breast cancer patients using tamoxifen.

Sanchez-Spitman AB, Moes DA, Gelderblom H, Dezentjé VO, Swen JJ, Guchelaar HJ.

Pharmacogenomics. 2017 Aug;18(12):1125-1132. doi: 10.2217/pgs-2017-0080. Epub 2017 Jul 26.

PMID:
28745555
30.

Limb Amputation after Multiple Treatments of Tenosynovial Giant Cell Tumour: Series of 4 Dutch Cases.

Mastboom MJL, Verspoor FGM, Gelderblom H, van de Sande MAJ.

Case Rep Orthop. 2017;2017:7402570. doi: 10.1155/2017/7402570. Epub 2017 Jun 28.

31.

Treatment patterns and clinical outcomes with pazopanib in patients with advanced soft tissue sarcomas in a compassionate use setting: results of the SPIRE study.

Gelderblom H, Judson IR, Benson C, Merimsky O, Grignani G, Katz D, Freivogel KW, Stein D, Jobanputra M, Mungul A, Manson SC, Sanfilippo R.

Acta Oncol. 2017 Dec;56(12):1769-1775. doi: 10.1080/0284186X.2017.1332779. Epub 2017 Jul 19.

PMID:
28723233
32.

Hepatitis B Virus Incidence and Risk Factors Among Human Immunodeficiency Virus-1 Negative Men Who Have Sex With Men in Kenya.

Wahome E, Ngetsa C, Mwambi J, Gelderblom HC, Manyonyi GO, Micheni M, Hassan A, Price MA, Graham SM, Sanders EJ.

Open Forum Infect Dis. 2016 Dec 7;4(1):ofw253. doi: 10.1093/ofid/ofw253. eCollection 2017 Winter.

33.

Does a glass of Coke boost the exposure to imatinib in gastrointestinal stromal tumour patients after gastrectomy?

Lubberman FJE, Gelderblom H, Wilmer CM, Kweekel DM, Desar IME, Colbers A, Burger D, van der Graaf WTA, van Erp N.

Br J Clin Pharmacol. 2017 Oct;83(10):2312-2314. doi: 10.1111/bcp.13333. Epub 2017 Jul 4. No abstract available.

PMID:
28677263
34.

High-Throughput Screening of Myxoid Liposarcoma Cell Lines: Survivin Is Essential for Tumor Growth.

de Graaff MA, Malu S, Guardiola I, Kruisselbrink AB, de Jong Y, Corver WE, Gelderblom H, Hwu P, Nielsen TO, Lazar AJ, Somaiah N, Bovée JVMG.

Transl Oncol. 2017 Aug;10(4):546-554. doi: 10.1016/j.tranon.2017.05.007. Epub 2017 Jun 24.

35.

Serum levels of IGF-1 and IGF-BP3 are associated with event-free survival in adult Ewing sarcoma patients treated with chemotherapy.

de Groot S, Gelderblom H, Fiocco M, Bovée JV, van der Hoeven JJ, Pijl H, Kroep JR.

Onco Targets Ther. 2017 Jun 13;10:2963-2970. doi: 10.2147/OTT.S123726. eCollection 2017.

36.

Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1-mutated or IDH2-mutated solid tumours.

Molenaar RJ, Coelen RJS, Khurshed M, Roos E, Caan MWA, van Linde ME, Kouwenhoven M, Bramer JAM, Bovée JVMG, Mathôt RA, Klümpen HJ, van Laarhoven HWM, van Noorden CJF, Vandertop WP, Gelderblom H, van Gulik TM, Wilmink JW.

BMJ Open. 2017 Jun 10;7(6):e014961. doi: 10.1136/bmjopen-2016-014961.

37.

Short-Course Radiotherapy Followed by Neoadjuvant Bevacizumab, Capecitabine, and Oxaliplatin and Subsequent Radical Treatment in Primary Stage IV Rectal Cancer: Long-Term Results of a Phase II Study.

Bisschop C, van Dijk TH, Beukema JC, Jansen RLH, Gelderblom H, de Jong KP, Rutten HJT, van de Velde CJH, Wiggers T, Havenga K, Hospers GAP.

Ann Surg Oncol. 2017 Sep;24(9):2632-2638. doi: 10.1245/s10434-017-5897-0. Epub 2017 May 30.

38.

Evaluation of Quality of Life at Progression in Patients with Soft Tissue Sarcoma.

Hudgens S, Forsythe A, Kontoudis I, D'Adamo D, Bird A, Gelderblom H.

Sarcoma. 2017;2017:2372135. doi: 10.1155/2017/2372135. Epub 2017 Apr 23.

39.

Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma.

Apellániz-Ruiz M, Diekstra MH, Roldán JM, Boven E, Castellano D, Gelderblom H, Mathijssen RHJ, Swen JJ, Böhringer S, García-Donás J, Rini BI, Guchelaar HJ, Rodríguez-Antona C.

Pharmacogenet Genomics. 2017 Jun;27(6):227-231. doi: 10.1097/FPC.0000000000000280.

PMID:
28430711
40.

A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors.

Wagner AJ, Kindler H, Gelderblom H, Schöffski P, Bauer S, Hohenberger P, Kopp HG, Lopez-Martin JA, Peeters M, Reichardt P, Qin A, Nippgen J, Ilaria RL, Rutkowski P.

Ann Oncol. 2017 Mar 1;28(3):541-546. doi: 10.1093/annonc/mdw659.

41.

Influence of CYP2C8 polymorphisms on imatinib steady-state trough level in chronic myeloid leukemia and gastrointestinal stromal tumor patients.

Verboom MC, Visser L, Kouwen S, Swen JJ, Diepstraten J, Posthuma WF, Gelderblom H, van Lammeren D, Wilms EB.

Pharmacogenet Genomics. 2017 Jun;27(6):223-226. doi: 10.1097/FPC.0000000000000278.

PMID:
28383355
42.

Giant cell tumour of bone in the denosumab era.

van der Heijden L, Dijkstra PDS, Blay JY, Gelderblom H.

Eur J Cancer. 2017 May;77:75-83. doi: 10.1016/j.ejca.2017.02.021. Epub 2017 Mar 30. Review.

PMID:
28365529
43.

Influenza vaccination in adult patients with solid tumours treated with chemotherapy.

Vollaard A, Schreuder I, Slok-Raijmakers L, Opstelten W, Rimmelzwaan G, Gelderblom H.

Eur J Cancer. 2017 May;76:134-143. doi: 10.1016/j.ejca.2017.02.012. Epub 2017 Mar 17. Review.

PMID:
28324748
44.

Bupropion for the treatment of apathy in Huntington's disease: A multicenter, randomised, double-blind, placebo-controlled, prospective crossover trial.

Gelderblom H, Wüstenberg T, McLean T, Mütze L, Fischer W, Saft C, Hoffmann R, Süssmuth S, Schlattmann P, van Duijn E, Landwehrmeyer B, Priller J.

PLoS One. 2017 Mar 21;12(3):e0173872. doi: 10.1371/journal.pone.0173872. eCollection 2017.

45.

Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients.

Farag S, Somaiah N, Choi H, Heeres B, Wang WL, van Boven H, Nederlof P, Benjamin R, van der Graaf W, Grunhagen D, Boonstra PA, Reyners AK, Gelderblom H, Steeghs N.

Eur J Cancer. 2017 May;76:76-83. doi: 10.1016/j.ejca.2017.02.007. Epub 2017 Mar 8.

PMID:
28284172
46.

Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group.

Stacchiotti S, Gronchi A, Fossati P, Akiyama T, Alapetite C, Baumann M, Blay JY, Bolle S, Boriani S, Bruzzi P, Capanna R, Caraceni A, Casadei R, Colia V, Debus J, Delaney T, Desai A, Dileo P, Dijkstra S, Doglietto F, Flanagan A, Froelich S, Gardner PA, Gelderblom H, Gokaslan ZL, Haas R, Heery C, Hindi N, Hohenberger P, Hornicek F, Imai R, Jeys L, Jones RL, Kasper B, Kawai A, Krengli M, Leithner A, Logowska I, Martin Broto J, Mazzatenta D, Morosi C, Nicolai P, Norum OJ, Patel S, Penel N, Picci P, Pilotti S, Radaelli S, Ricchini F, Rutkowski P, Scheipl S, Sen C, Tamborini E, Thornton KA, Timmermann B, Torri V, Tunn PU, Uhl M, Yamada Y, Weber DC, Vanel D, Varga PP, Vleggeert-Lankamp CLA, Casali PG, Sommer J.

Ann Oncol. 2017 Jun 1;28(6):1230-1242. doi: 10.1093/annonc/mdx054. Review.

47.

Central venous access related adverse events after trabectedin infusions in soft tissue sarcoma patients; experience and management in a nationwide multi-center study.

Verboom MC, Ouwerkerk J, Steeghs N, Lutjeboer J, Martijn Kerst J, van der Graaf WTA, Reyners AKL, Sleijfer S, Gelderblom H.

Clin Sarcoma Res. 2017 Jan 31;7:2. doi: 10.1186/s13569-017-0066-6. eCollection 2017.

48.

Genetic polymorphisms as predictive biomarker of survival in patients with gastrointestinal stromal tumors treated with sunitinib.

Kloth JSL, Verboom MC, Swen JJ, van der Straaten T, Sleijfer S, Reyners AKL, Steeghs N, Gelderblom H, Guchelaar HJ, Mathijssen RHJ.

Pharmacogenomics J. 2018 Jan;18(1):49-55. doi: 10.1038/tpj.2016.83. Epub 2017 Jan 24.

PMID:
28117434
49.

Investigating the heterogeneity of alkylating agents' efficacy and toxicity between sexes: A systematic review and meta-analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study).

Fresneau B, Hackshaw A, Hawkins DS, Paulussen M, Anderson JR, Judson I, Litière S, Dirksen U, Lewis I, van den Berg H, Gaspar N, Gelderblom H, Whelan J, Boddy AV, Wheatley K, Pignon JP, De Vathaire F, Le Deley MC, Le Teuff G.

Pediatr Blood Cancer. 2017 Aug;64(8). doi: 10.1002/pbc.26457. Epub 2017 Jan 23. Review.

PMID:
28111876
50.

Tumor LINE-1 Methylation Level in Association with Survival of Patients with Stage II Colon Cancer.

Swets M, Zaalberg A, Boot A, van Wezel T, Frouws MA, Bastiaannet E, Gelderblom H, van de Velde CJ, Kuppen PJ.

Int J Mol Sci. 2016 Dec 27;18(1). pii: E36. doi: 10.3390/ijms18010036.

Supplemental Content

Loading ...
Support Center